Band 9: Some people say that drug companies have a responsibility to spend money on researching medicines that will help people in poorer countries. Others say the main responsibility of drug companies is to make money.

The debate over the responsibilities of pharmaceutical corporations often centers around a moral dilemma: should they prioritize profit or invest in the health needs of impoverished nations? In this essay, I will discuss both perspectives and argue that while pharmaceuticals are inherently profit-driven entities, they also have an ethical obligation to address the pressing health needs of less affluent countries.

On the one hand, it’s undeniable that pharmaceutical companies operate within a commercial paradigm, where research, development, and marketing of medicines require significant capital. For instance, the creation of drugs for rare diseases often involves hefty investments due to the limited target market. Consequently, setting prices that reflect these costs becomes crucial for recuperating investments and funding future research. Furthermore, these corporations have a duty to their shareholders and employees to generate profits. This capitalistic framework is foundational to their operation, prompting them to set prices that ensure sustainability.

However, a purely profit-driven approach can inadvertently marginalize vulnerable populations. High drug prices often render essential medications inaccessible to those in developing nations, exacerbating global health inequalities. For instance, the HIV/AIDS crisis in Africa during the late 20th century highlighted this disparity. While antiretroviral treatments were available, their exorbitant costs made them unreachable for many, leading to countless preventable deaths. Such scenarios underline the moral obligation pharmaceuticals have beyond their commercial interests. Collaborative efforts, like the COVAX initiative for COVID-19 vaccines, demonstrate how these corporations can play a pivotal role in global health equity. By offering tiered pricing or donating medicines, they can contribute to a more just distribution of health resources globally.

In conclusion, pharmaceutical companies, while profit-driven, must also consider the global health implications of their pricing. Balancing commercial goals with ethical duties can lead to a fairer global health landscape.